For the first time, our studies showed increased STAT3 activation in tumor cells, tumor-associated immune cells, and CAFs in tumor biopsies from ovarian cancer patients that progressed following PARPi treatment. The gene discussed is STAT3; the disease is ovarian carcinoma.